Switching Reactive Oxygen Species into Reactive Nitrogen Species by Photocleaved O 2 ‐Released Nanoplatforms Favors Hypoxic Tumor Repression

Tao Luo,Duo Wang,Lidong Liu,Yan Zhang,Chuangye Han,Ying Xie,Yan Liu,Jingchen Liang,Guanhua Qiu,Hongxue Li,Danke Su,Junjie Liu,Kun Zhang

DOI: https://doi.org/10.1002/advs.202101065

IF: 15.1

2021-08-08

Advanced Science

Abstract:In various reactive oxygen species (ROS)-based antitumor approaches (e.g., photodynamic therapy), increasing attentions are made to improve ROS level, but the short lifetime that is another decisive hurdle of ROS-based antitumor outcomes is not even explored yet. To address it, a photocleaved O2-released nanoplatform is constructed to release and switch ROS into reactive nitrogen species (RNS) for repressing hypoxic breast tumor. Systematic explorations validate that the nanoplatforms can attain continuous photocontrolled O2 release, alleviate hypoxia, and elevate ROS level. More significantly, the entrapped PDE5 inhibitor (PDE5-i) in this nanoplatform can be enzymatically decomposed into nitric oxide that further combines with ROS to generate RNS, enabling the persistent antitumor effect since RNS features longer lifetime than ROS. Intriguingly, ROS conversion into RNS can help ROS to evade the hypoxia-induced resistance to ROS-based antitumor. Eventually, RNS production unlocks robust antitumor performances along with ROS elevation and hypoxia mitigation. Moreover, this extraordinary conversion from ROS into RNS also can act as a general method to solve the short lifetime of ROS.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is the short - lifetime (SLT) problem of reactive oxygen species (ROS) in photodynamic therapy (PDT). This causes ROS to disappear rapidly before reaching the tumor cell nucleus or mitochondria, thus affecting the treatment effect. To overcome this obstacle, the researchers constructed a photolabile oxygen - releasing nanoplatform (Ce6/PDE5 - i@FHMON - O2). This platform can release oxygen and convert ROS into reactive nitrogen species (RNS) with a longer lifetime to enhance the inhibitory effect on hypoxic breast tumors. Specifically, the study solved the problem in the following ways: 1. **Oxygen supply and hypoxia alleviation**: The nanoplatform can absorb and respond to near - infrared (NIR) light to release oxygen, alleviating the hypoxic state in the tumor microenvironment, thereby improving the generation efficiency of ROS. 2. **Conversion from ROS to RNS**: The PDE5 inhibitor (PDE5 - i) loaded in the nanoplatform can be enzymatically decomposed to produce nitric oxide (NO). NO further combines with ROS to generate RNS, such as peroxynitrite (ONOO\(^-\)). Since RNS has a longer half - life (about 10\(^{-2}\) seconds) than ROS, it can continuously play an anti - tumor role. 3. **Verification of anti - tumor effect**: Through in vitro and in vivo experiments, the effectiveness of this nanoplatform in alleviating hypoxia, increasing ROS levels, and converting to RNS was verified, and finally, effective inhibition of hypoxic breast tumors was achieved. In conclusion, this study provides a new strategy to solve the short - lifetime problem of ROS by converting ROS to RNS, thereby improving the treatment effect of photodynamic therapy.

Switching Reactive Oxygen Species into Reactive Nitrogen Species by Photocleaved O 2 ‐Released Nanoplatforms Favors Hypoxic Tumor Repression

Switching Reactive Oxygen Species into Reactive Nitrogen Species by Photocleaved O2‐Released Nanoplatforms Favors Hypoxic Tumor Repression

Overcoming oxygen heterogeneity of tumor microenvironments to boost cancer immunotherapy by oxygen-switchable ROS/RNS nanogenerators

Long‐Lasting Reactive Oxygen Species Generation by Porous Redox Mediator‐Potentiated Nanoreactor for Effective Tumor Therapy

Tumor microenvironment-responsive nanosystem achieves reactive oxygen species self-cycling after photothermal induction to enhance efficacy of antitumor therapy

Reactive Oxygen Species Activatable Heterodimeric Prodrug as Tumor-Selective Nanotheranostics

Oxygen Self‐Supplying Enzymatic Nanoplatform for Precise and Enhanced Photodynamic Therapy

Tumor Oxygenation and Hypoxia Inducible Factor-1 Functional Inhibition Via a Reactive Oxygen Species Responsive Nanoplatform for Enhancing Radiation Therapy and Abscopal Effects.

Nanomaterials for Tumor Hypoxia Relief to Improve the Efficacy of ROS-Generated Cancer Therapy

Engineering a Synergistic Antioxidant Inhibition Nanoplatform to Enhance Oxidative Damage in Tumor Treatment

Reactive Oxygen Species–Activatable Liposomes Regulating Hypoxic Tumor Microenvironment for Synergistic Photo/Chemodynamic Therapies

Clinical Vision Characteristics of the Congenital Achromatopsias. I. Visual Acuity, Refractive Error, and Binocular Status

Multifaceted Elevation of ROS Generation for Effective Cancer Suppression

Integrated energy conversion units in nanoscale frameworks induce sustained generation and amplified lethality of singlet oxygen in oxidative therapy of tumor

ROS-sensitive biomimetic nanocarriers modulate tumor hypoxia for synergistic photodynamic chemotherapy

A Photo‐Activated Continuous Reactive Oxygen Species Nanoamplifier for Dual‐Dynamic Cascade Cancer Therapy

A photo and tumor microenvironment activated nano-enzyme with enhanced ROS generation and hypoxia relief for efficient cancer therapy

Dual-Mode Reactive Oxygen Species-Stimulated Carbon Monoxide Release for Synergistic Photodynamic and Gas Tumor Therapy

Precise Regulation of Reactive Oxygen Species in Tumor Microenvironment for Alleviating Inhibitory Immunogenic Cell Death

Tumor Microenvironment-Responsive Theranostic Nanoplatform for Guided Molecular Dynamic/Photodynamic Synergistic Therapy

All-in-One Theranostic Nanoagent with Enhanced Reactive Oxygen Species Generation and Modulating Tumor Microenvironment Ability for Effective Tumor Eradication.